| (Values in U.S. Thousands) | Dec, 2025 | Sep, 2025 | Jun, 2025 | Sep, 2024 | Jun, 2024 |
| Sales | 292,890 | 216,830 | 181,400 | 101,620 | 100,050 |
| Sales Growth | +35.08% | +19.53% | +78.51% | +1.57% | +32.11% |
| Net Income | 81,960 | 24,330 | -71,790 | -67,730 | -66,190 |
| Net Income Growth | +236.87% | +133.89% | -5.99% | -2.33% | -10,406.37% |
Caris Life Sciences Inc (CAI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Caris Life Sciences Inc. provides diagnostics and anatomic pathology services. It develops an unbiased profiling platform for novel target identification, drug development and delivery, diagnostic and disease monitoring and precision medicine enabling aspects. Caris Life Sciences Inc. is based in Irving, TX.
Fiscal Year End Date: 12/31